Ultragenyx Pharmaceutical (RARE) Could Be 42% Undervalued On EMA Filing Progress

Ultragenyx Pharmaceutical (RARE) is back in focus after the European Medicines Agency validated its Marketing Authorisation Application for rebisufligene etisparvovec in Sanfilippo syndrome Type A, following recent FDA approval in the United States.

Ultragenyx Pharmaceutical shares have risen in the very short term, with a 1-day share price return of 3.19% and a 7-day gain of 4.97%. However, the 30-day and 90-day share price returns are down 42.63% and 54.53% respectively, and the 1-year total shareholder return has declined 51.23%. This suggests that the recent EMA validation and prior FDA approval are being weighed against a longer track record of weak investor returns and changing perspectives on both growth potential and risk.

Scan a curated set of rare-disease and specialist biotech opportunities that are moving on fresh catalysts by starting with 19 high quality undiscovered gems tied to stories like Ultragenyx Pharmaceutical's latest gene therapy milestone.

Ultragenyx Pharmaceutical now trades at a steep discount to both analyst targets and some intrinsic value estimates after a sharp pullback. Is that pricing in gene therapy execution risk sensibly, or overshooting caution?

Most Popular Narrative: 41.5% Undervalued

The most followed valuation storyline pegs Ultragenyx Pharmaceutical at a fair value of $26 per share versus a last close of $15.22, which frames the current slide as a disconnect between science and financial structure rather than sentiment alone.

The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine:

See why 1 investors see Ultragenyx Pharmaceutical as 41% undervalued.

Result: Fair Value of $26 (UNDERVALUED)

Still, two things could break this Ultragenyx Pharmaceutical undervaluation story wide open if they go wrong: gene therapy commercialization strain and ongoing heavy losses.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

Mixed messages in Ultragenyx Pharmaceutical's story today. Act while the narrative is still forming, and weigh the 2 key rewards and 3 important warning signs against your own reading of the data.

Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

Do not stop with Ultragenyx Pharmaceutical. Use the screener to surface fresh ideas that match your style before the next wave of opportunities moves without you.

• Target steadier compounding potential by scanning a curated pool of resilient businesses through 31 resilient stocks with low risk scores that aim to limit downside shocks.
• Hunt for potential value setups by filtering for quality companies trading below implied worth using the focused 31 high quality undervalued stocks results.
• Build a watchlist of balance sheet strength by zeroing in on companies with robust finances via the list of solid balance sheet and fundamentals (26 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com